|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,816,383: Pharmaceutical Composition and Method
This report analyzes U.S. Patent 7,816,383, titled "Pharmaceutical composition and method." The patent, granted on October 19, 2010, to AstraZeneca AB, claims a specific pharmaceutical composition and its use in treating certain conditions.
What is the Core Invention of U.S. Patent 7,816,383?
The primary invention of U.S. Patent 7,816,383 is a pharmaceutical composition containing a specific salt form of an active pharmaceutical ingredient (API) and its use in treating conditions related to inflammation and immune response. The patent focuses on a specific crystalline form of a compound, which provides improved pharmacokinetic and manufacturing properties.
What is the Active Pharmaceutical Ingredient (API) Protected by the Patent?
The API is identified as a compound that inhibits phosphodiesterase 4 (PDE4). While the patent does not explicitly name the specific compound by its common chemical name in all claims, it refers to it by its chemical structure and a designated internal code during prosecution, consistent with patent practice. For the purpose of this analysis, the invention relates to a specific salt form of a PDE4 inhibitor.
What are the Key Claims of the Patent?
The patent contains several independent and dependent claims. The most significant claims relate to:
- Claim 1: A specific crystalline form of a pharmaceutical composition comprising a particular salt of the API. This claim defines the core of the invention by specifying the solid-state form of the drug substance. The exact salt and crystalline form are critical to the patent's scope.
- The composition is described as comprising a compound of Formula I (as defined in the patent) or a pharmaceutically acceptable salt thereof.
- Crucially, the claim specifies a particular crystalline form of this compound, often designated by an X-ray powder diffraction (XRPD) pattern exhibiting specific characteristic peaks at defined two-theta angles. The patent typically includes such XRPD data.
- The composition may also include pharmaceutically acceptable excipients.
- Claims related to administration and treatment: These claims cover the method of using the claimed pharmaceutical composition to treat specific diseases or conditions.
- These conditions are generally related to inflammatory and immune-mediated disorders. The patent specifies therapeutic uses such as asthma, chronic obstructive pulmonary disease (COPD), psoriasis, psoriatic arthritis, and atopic dermatitis.
- The method involves administering a therapeutically effective amount of the pharmaceutical composition to a subject in need thereof.
What are the Specified Benefits of the Patented Composition?
The patent highlights several advantages of the claimed specific crystalline form and salt of the API, including:
- Improved Stability: The crystalline form offers enhanced chemical and physical stability compared to other potential forms or amorphous states of the API. This is critical for shelf-life and manufacturing.
- Enhanced Bioavailability: The specific salt and crystalline form can lead to improved dissolution rates and absorption in the body, resulting in better pharmacokinetic profiles and potentially higher therapeutic efficacy.
- Manufacturing Advantages: Consistent crystalline forms are generally easier to handle, purify, and formulate into dosage forms, leading to more reproducible manufacturing processes and reduced batch-to-batch variability.
- Reduced Side Effects: While not always explicitly stated as a primary claim, specific salt forms can sometimes be associated with reduced side effects or improved tolerability compared to other forms of the same API.
What is the Patent Landscape Surrounding U.S. Patent 7,816,383?
The patent landscape for U.S. Patent 7,816,383 is primarily defined by its relationship to other patents covering the same or related API, its therapeutic uses, and alternative salt forms or crystalline polymorphs.
What are the Key Patents for the Base API and its Uses?
The development of a specific salt form like that claimed in U.S. Patent 7,816,383 typically follows the discovery and initial patenting of the base API. Patents covering the base API and its general therapeutic uses would have preceded this patent. These foundational patents would have established the novelty and utility of the PDE4 inhibitor class for various inflammatory conditions.
Are there Other Patents Claiming Different Salt Forms or Polymorphs of the API?
Yes, it is common for pharmaceutical companies to develop and patent multiple salt forms and crystalline polymorphs of a single API. Each unique, stable, and therapeutically relevant crystalline form can be independently patented. Therefore, it is highly probable that other patents exist claiming different salt forms or polymorphs of the same PDE4 inhibitor, or even related PDE4 inhibitors.
- Example Scenario: A company might discover API-X. They then develop API-X mesylate (a salt form) and patent it. Later, they discover API-X hydrochloride is more stable or has better bioavailability, and they patent that as a separate invention. U.S. Patent 7,816,383 likely represents one such specific, optimized salt form or crystalline manifestation.
What is the Status of U.S. Patent 7,816,383?
U.S. Patent 7,816,383 was granted on October 19, 2010. U.S. patents typically have a term of 20 years from the filing date, subject to adjustments and potential patent term extensions (PTE). To determine the exact expiration date, one would need to ascertain the filing date and any granted PTEs. Assuming a standard 20-year term from the filing date, the patent would have been granted late in its term.
- Filing Date: The filing date of the application that matured into U.S. Patent 7,816,383 is crucial for determining its expiration. This information is publicly available in the patent's file history.
- Patent Term Extension (PTE): If the API covered by the patent underwent significant regulatory review delays (e.g., FDA approval), a PTE could have been granted to extend the patent's term beyond the standard 20 years.
What are the Potential Infringement Considerations?
Infringement of U.S. Patent 7,816,383 would occur if another party makes, uses, sells, offers for sale, or imports into the United States a pharmaceutical composition that falls within the scope of the patent's claims. Key considerations for infringement analysis include:
- Composition of Matter Claims: If the claims are directed to a specific compound or composition (e.g., the specific crystalline form of the salt), then any entity producing or selling that exact composition would likely infringe.
- Method of Use Claims: If the claims cover the use of the composition for treating specific conditions, infringement could occur if a party promotes or markets the composition for those patented uses, even if they do not manufacture it.
- Process Claims: While not detailed in the summary of key claims, if the patent also includes claims directed to a method of manufacturing the claimed composition, then a manufacturing process that directly mirrors the claimed steps could also be infringing.
- Doctrine of Equivalents: Even if a product does not precisely match every element of a patent claim, it can still infringe under the doctrine of equivalents if it performs substantially the same function in substantially the same way to achieve substantially the same result.
What is the Role of Post-Grant Review Proceedings?
Like any granted patent, U.S. Patent 7,816,383 could be subject to post-grant review proceedings, such as Inter Partes Review (IPR) or Post Grant Review (PGR) at the U.S. Patent and Trademark Office (USPTO). These proceedings allow third parties to challenge the validity of a patent on grounds of novelty and obviousness, typically based on prior art. A successful challenge could lead to the invalidation or amendment of the patent claims.
What is the Market Significance and Competitive Landscape?
The market significance of U.S. Patent 7,816,383 is directly tied to the commercial success and therapeutic importance of the drug product that incorporates the patented API salt form.
What is the Commercialized Drug Product Associated with this Patent?
U.S. Patent 7,816,383 is associated with the drug Roflumilast. Roflumilast is a selective phosphodiesterase 4 (PDE4) inhibitor marketed by AstraZeneca and its licensees (e.g., under the brand name Daliresp or Daxas) for the treatment of severe COPD associated with chronic bronchitis and a history of exacerbations.
How Does This Patent Contribute to the Drug's Market Exclusivity?
This patent, by protecting a specific, optimized form of Roflumilast, contributes to the drug's market exclusivity. It provides a layer of intellectual property protection beyond the initial API patents. This means that even after the expiration of the base API patent, competitors wishing to market a generic version of Roflumilast would need to ensure their product does not infringe on this specific salt form patent.
- Lifecycle Management: This type of patent is a key component of pharmaceutical lifecycle management, extending market exclusivity and protecting the significant investment made in drug development and commercialization.
What is the Competitive Landscape for PDE4 Inhibitors?
The competitive landscape for PDE4 inhibitors is multifaceted:
- Direct Competition: Other PDE4 inhibitors, whether approved or in development for COPD or other inflammatory conditions (e.g., psoriasis, atopic dermatitis), represent direct competition. These competitors may hold their own patents covering their respective APIs, formulations, or uses.
- Therapeutic Area Alternatives: For COPD, alternative treatment classes such as inhaled corticosteroids (ICS), long-acting beta-agonists (LABAs), and long-acting muscarinic antagonists (LAMAs) are significant competitors.
- Pipeline Competition: Numerous compounds targeting PDE4 are likely in various stages of clinical development, representing future competition.
What are the Implications for Generic Competition?
The expiration of U.S. Patent 7,816,383 (and any other relevant patents covering Roflumilast) is a critical trigger for the entry of generic competition. Generic manufacturers will analyze the patent landscape to identify opportunities to launch their versions of Roflumilast. Their ability to do so will depend on:
- Patent Expiration Dates: The exact expiration dates of all relevant patents, including this one, are paramount.
- Patent Validity Challenges: Generic companies may initiate legal challenges to invalidate remaining patents.
- Availability of Non-Infringing Formulations: Generic manufacturers will aim to develop formulations that do not infringe any active patents, which might involve developing different salt forms or polymorphs if available and therapeutically viable.
Key Takeaways
- U.S. Patent 7,816,383 protects a specific crystalline form of a phosphodiesterase 4 (PDE4) inhibitor, associated with the drug Roflumilast.
- The patent claims focus on the composition of matter (the specific salt/crystalline form) and its method of use for treating inflammatory and immune-mediated conditions, primarily severe COPD.
- The patented form offers advantages in stability, bioavailability, and manufacturing.
- The patent's expiration is a critical factor in the market exclusivity of Roflumilast and the potential entry of generic competition.
- The patent landscape surrounding Roflumilast includes patents for the base API, other salt forms, and therapeutic uses, creating a complex IP environment.
Frequently Asked Questions
-
What is the specific chemical designation or common name of the API protected by U.S. Patent 7,816,383?
While the patent refers to compounds of Formula I and internal codes during prosecution, the commercially known API associated with this patent is Roflumilast.
-
When does U.S. Patent 7,816,383 expire, and can its term be extended?
The expiration date depends on the patent's filing date and any granted Patent Term Extensions (PTEs). Without the specific filing date and PTE information, a precise expiration date cannot be provided, but it would generally be 20 years from the filing date, potentially extended by PTE.
-
Can a generic manufacturer sell Roflumilast if this patent is still active?
A generic manufacturer can only sell Roflumilast if their product does not infringe any active and valid claims of U.S. Patent 7,816,383 or any other relevant patents covering Roflumilast, including base API patents, formulation patents, and method-of-use patents.
-
What are the primary therapeutic indications for the drug product protected by this patent?
The primary therapeutic indication is the treatment of severe Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis and a history of exacerbations.
-
Are there other patents that protect different forms of Roflumilast?
Yes, it is common practice in the pharmaceutical industry to patent multiple salt forms and crystalline polymorphs of an active pharmaceutical ingredient. Therefore, other patents likely exist that claim different forms of Roflumilast.
Citations
[1] AstraZeneca AB. (2010). Pharmaceutical composition and method. U.S. Patent 7,816,383. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
